Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to -$2.2 million.

  • Mirum Pharmaceuticals' Cash from Investing Activities rose 8765.25% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.3 million, marking a year-over-year increase of 7378.46%. This contributed to the annual value of -$90.1 million for FY2024, which is 1592.82% up from last year.
  • Mirum Pharmaceuticals' Cash from Investing Activities amounted to -$2.2 million in Q3 2025, which was up 8765.25% from -$6.6 million recorded in Q2 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' Cash from Investing Activities peaked at $108.0 million during Q4 2021, and registered a low of -$182.8 million during Q3 2023.
  • In the last 5 years, Mirum Pharmaceuticals' Cash from Investing Activities had a median value of -$2.2 million in 2025 and averaged -$8.7 million.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Cash from Investing Activities soared by 228404.77% in 2021, and later tumbled by 12400769.23% in 2025.
  • Mirum Pharmaceuticals' Cash from Investing Activities (Quarter) stood at $108.0 million in 2021, then crashed by 75.23% to $26.8 million in 2022, then tumbled by 107.47% to -$2.0 million in 2023, then surged by 132.05% to $641000.0 in 2024, then tumbled by 447.43% to -$2.2 million in 2025.
  • Its Cash from Investing Activities was -$2.2 million in Q3 2025, compared to -$6.6 million in Q2 2025 and -$16.1 million in Q1 2025.